AnaptysBio Inc (ANAB)
Healthcare
Biotechnology
53.70 $
+0.6%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns AnaptysBio Inc (ANAB)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 66.8% of the shares are freely tradable; institutional investors hold 104.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
104.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
5.8%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
66.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
37.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
30Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 26.61 | 7,880,094 | +0.0 | 03/31/2026 |
| BlackRock Inc | 5.68 | 1,681,380 | -3.1 | 03/31/2026 |
| TANG CAPITAL MANAGEMENT LLC | 4.49 | 1,330,879 | -0.1 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 3.36 | 993,905 | -3.9 | 03/31/2026 |
| State Street Corp | 3.35 | 992,445 | -5.8 | 03/31/2026 |
| Affinity Asset Advisors, LLC | 3.17 | 940,000 | +111.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.88 | 853,151 | +0.0 | 03/31/2026 |
| Sanofi | 2.78 | 821,917 | +0.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 2.62 | 775,836 | -0.3 | 07/28/2026 |
| Vanguard Morn Total Stk Mkt Idx Investor | 2.19 | 648,146 | +1.3 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.